VALERITAS HOLDINGS COM (NASDAQ:VLRX) target price raised to $7.50, reported today by B. Riley
- Updated: October 1, 2016
Yesterday VALERITAS HOLDINGS COM (NASDAQ:VLRX) traded 0.00% even at $0.00. The company’s 50-day moving average is $5.62 and its 200-day moving average is $5.71. The last stock close price is down 5.08% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 500
VALERITAS HOLDINGS COM (NASDAQ:VLRX) had its target price raised to $7.50 by B. Riley in a report released 10/02/2016. The new target price indicates steady performance relative to the company's last stock close price.
Previously on 9/26/2016, B. Riley reported about VALERITAS HOLDINGS COM (NASDAQ:VLRX) raised the target price from $0.00 to $7.50. At the time, this indicated a possible upside of 0%.
See Chart Below
VALERITAS HOLDINGS COM has a 52 week low of $5.00 and a 52 week high of $6.50 The company’s market cap is currently $0.
About VALERITAS HOLDINGS COM (NASDAQ:VLRX)
Valeritas, Inc. is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company's portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin. Its development portfolio also includes the h-Patch technology, the Mini-Ject pre-filled needle-free delivery system and the Micro-Trans microneedle transdermal delivery patch. Its h-Patch is a controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. The Mini-Ject represents needle-free injection system, combining a range of fully disposable pre-filled options. Micro-Trans microneedle array patch technology enables drug delivery into the dermis without limitations of drug size, structure, charge or the patient's skin characteristics.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.